Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$6.88 USD

6.88
4,300,566

-0.07 (-1.01%)

Updated May 10, 2024 04:00 PM ET

After-Market: $6.89 +0.01 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 251)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug

Bristol-Myers Squibb (BMY) announces encouraging data from a phase II study on plaque psoriasis candidate.

    Why Is Bausch (BHC) Down 10% Since Last Earnings Report?

    Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis

      Bausch Health Companies Inc. (BHC) resubmits its NDA for plaque psoriasis drug, Duobrii to the FDA and the agency has set a PDUFA action date of Feb 15, 2019.

        Zacks.com headshot

        Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris

        Bausch (BHC) advances its dermatology portfolio with the FDA approval of Altreno for acne vulgaris.

          Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well

          Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

            Bausch Health (BHC) Q2 Earnings and Revenues Surpass Estimates

            Bausch (BHC) delivered earnings and revenue surprises of 14.81% and 3.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

              Can Tenet Healthcare (THC) Keep Earnings Beat Alive in Q2?

              Tenet Healthcare (THC) is likely to repeat its success story in Q2 on the back of a strong performance at the Conifer segment as well as its key initiatives.